Skip to main content

Table 3 Multivariate analysis in HGOC patients

From: BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer

Variable

 

Progression-free survival

Overall survival

HR of progression (95% CI)

P-value

HR of death (95% CI)

P value

A

FIGO stage

I/II versus III/IV

2.5 (1.0–6.3)

0.048

1.6 (0.6–4.1)

0.310

Residual disease

no versus yes

2.2 (1.4–3.5)

 < 0.001

2.5 (1.5–4.2)

 < 0.001

Histology

HGSOC versus HGEOC

–

–

0.7 (0.3–1.3)

0.257

BRCA-LOF

no versus yes

0.5 (0.3–0.8)

0.007

0.6 (0.3–0.9)

0.022

B

FIGO stage

I/II versus III/IV

2.6 (1.0–6.6)

0.041

1.6 (0.6–4.1)

0.320

Residual disease

no versus yes

2.0 (1.3–3.2)

0.002

2.3 (1.4–3.9)

0.001

Histology

HGSOC versus HGEOC

–

–

0.7 (0.3–1.4)

0.301

BRCA genetic aberrations

no versus yes

0.7 (0.4–1.1)

0.099

0.7 (0.4–1.1)

0.152

C

FIGO stage

I/II versus III/IV

2.1 (0.8–6.1)

0.154

1.5 (0.6–4.0)

0.374

Residual disease

no versus yes

2.3 (1.3–4.2)

0.007

2.1 (1.2–3.7)

0.012

Histology

HGSOC versus HGEOC

–

–

0.6 (0.3–1.2)

0.149

BRCA-LOF

no versus yes

0.4 (0.2–0.8)

0.007

0.5 (0.3–0.9)

0.012

  1. Clinicopathological features and (A) BRCA-LOF by epigenetic or genetic aberrations and (B) BRCA mutational status in 131 patients. (C) Clinicopathological features and BRCA-LOF in the subgroup of 77 patients without maintenance therapy with bevacizumab
  2. The significance level was determined by Cox regression analysis
  3. Bold values indicate P values < 0.05
  4. CI confidence interval; FIGO International Federation of Gynecology and Obstetrics; HGEOC high-grade endometrioid ovarian cancer; HGSOC high-grade serous ovarian cancer; HR hazard ratio; HRD homologous recombination deficiency; LOF loss of function
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us